Mylan price target raised to $32 from $28 at Mizuho

Mizuho analyst Irina Koffler raised her price target for Mylan (MYL) to $32 after the company received its “hard-fought” FDA approval for generic Advair, a $1.5B inhaler product in the U.S. The analyst, however, reiterates a Neutral rating on the shares. She remains cautious on Mylan’s longer-term growth outlook and strategy.

https://thefly.com/landingPageNews.php?id=2856487